GlassScriptPhysician profile
Roman Spivak
NPI 1780889493
$140,370.68
in general payments reported to CMS, 2019-2025
38 companies · $4,079 in 2025
The $4,079 reported for 2025 was more than what 86% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,170 · 2020: $9,691 · 2021: $26K · 2022: $39K · 2023: $54K · 2024: $6,756 · 2025: $4,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $54K · Food and Beverage: $6,636 · Consulting Fee: $1,950 · Travel and Lodging: $1,915 · Education: $363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $53,625.00 |
| Food and Beverage | $6,635.92 |
| Consulting Fee | $1,950.00 |
| Travel and Lodging | $1,915.30 |
| Education | $362.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $131,255.20 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,526.52 | 2019-2025 | Breztri, Fasenra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $761.39 | 2019-2025 | Stiolto Respimat, Spiriva Respimat, Ofev |
| Medtronic, INC. | $758.30 | 2024-2025 | Illumisite |
| Genentech USA, INC. | $463.07 | 2019-2025 | Xolair |
| Mylan Specialty L.P. | $390.64 | 2020-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $370.81 | 2021-2025 | Dupixent |
| Sunovion Pharmaceuticals INC. | $348.63 | 2019-2021 | |
| Abbott Laboratories | $302.59 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $283.71 | 2021-2025 | Glassia |
| Genzyme Corporation | $278.60 | 2021-2025 | |
| Baxter Healthcare | $231.13 | 2022-2025 | Hillrom - Monarch Airway Clearance System |
| Electromed, INC. | $203.17 | 2021-2025 | Smartvest |
| Sanofi-Aventis U.S. LLC | $184.94 | 2024-2025 | |
| Resmed Corp | $176.55 | 2024 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $159.61 | 2025 | Ohtuvayre |
| Ethicon INC. | $144.34 | 2019 | |
| Novartis Pharmaceuticals Corporation | $141.83 | 2019-2023 | |
| Insmed, INC. | $138.31 | 2019-2025 | Arikayce, Brinsupri |
| Janssen Pharmaceuticals, INC | $129.64 | 2021-2022 | |
| Inspire Medical Systems, INC. | $129.01 | 2023-2025 | Inspire |
| Boston Scientific Corporation | $116.57 | 2022-2023 | Exalt Model D, Coredx |
| Amgen INC. | $111.53 | 2023-2025 | Tezspire |
| Advanced Respiratory, INC | $96.94 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $96.54 | 2021-2024 | Keytruda |
| Lilly USA, LLC | $87.50 | 2025 | Zepbound |
| Viatris Specialty LLC | $72.39 | 2025 | Yupelri |
| Philips North America LLC | $71.02 | 2019-2025 | Vest Therapy Und |
| Haemonetics Corporation | $68.88 | 2023 | Teg6s Hemostasis System |
| Jazz Pharmaceuticals INC. | $57.76 | 2020-2021 | |
| Grifols USA, LLC | $44.42 | 2023 | Prolastin-C Liquid |
| Circassia INC. | $44.09 | 2019-2021 | |
| Shire North American Group INC | $43.08 | 2019 | |
| Pulmonx Corporation | $19.32 | 2024 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Mallinckrodt Hospital Products INC. | $18.99 | 2024 | Terlivaz |
| Actelion Pharmaceuticals US, INC. | $18.16 | 2023 | Opsumit, Uptravi |
| Vapotherm INC | $13.73 | 2022 | |
| Eisai INC. | $11.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roman Spivak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.